Recursion Pharmaceuticals Correlations
| RXRX Stock | USD 5.84 0.32 5.80% |
The current 90-days correlation between Recursion Pharmaceuticals and Verve Therapeutics is 0.07 (i.e., Significant diversification). The correlation of Recursion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Recursion Pharmaceuticals Correlation With Market
Very weak diversification
The correlation between Recursion Pharmaceuticals and DJI is 0.45 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Recursion Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Recursion | Build AI portfolio with Recursion Stock |
Moving together with Recursion Stock
Moving against Recursion Stock
| 0.58 | BCH | Banco De Chile | PairCorr |
| 0.44 | INCR | INC Research Holdings | PairCorr |
| 0.67 | TRV | The Travelers Companies | PairCorr |
| 0.63 | HPQ | HP Inc | PairCorr |
| 0.45 | WMT | Walmart Sell-off Trend | PairCorr |
| 0.37 | HD | Home Depot | PairCorr |
Related Correlations Analysis
| 0.4 | 0.15 | 0.29 | 0.33 | 0.19 | ZURA | ||
| 0.4 | 0.66 | 0.5 | 0.58 | 0.39 | ELEV | ||
| 0.15 | 0.66 | 0.81 | 0.78 | 0.52 | VERV | ||
| 0.29 | 0.5 | 0.81 | 0.81 | 0.66 | SANA | ||
| 0.33 | 0.58 | 0.78 | 0.81 | 0.74 | RLAY | ||
| 0.19 | 0.39 | 0.52 | 0.66 | 0.74 | RPTX | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Recursion Stock performing well and Recursion Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Recursion Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 4.56 | 0.95 | 0.21 | 1.12 | 3.57 | 10.79 | 26.66 | |||
| ELEV | 3.60 | 0.58 | 0.08 | (1.79) | 3.37 | 9.09 | 29.95 | |||
| VERV | 5.61 | 2.50 | 0.50 | (1.79) | 3.28 | 9.83 | 83.78 | |||
| SANA | 4.85 | 1.42 | 0.36 | 1.02 | 3.47 | 12.50 | 31.62 | |||
| RLAY | 3.14 | 0.33 | 0.09 | 0.35 | 3.74 | 6.55 | 16.42 | |||
| RPTX | 2.99 | 0.99 | 0.19 | (1.07) | 2.76 | 7.75 | 27.20 |
Recursion Pharmaceuticals Corporate Management
| Najat Khan | Chief Officer | Profile | |
| Christopher Gibson | CEO CoFounder | Profile | |
| Kevin Leggat | Vice Accounting | Profile | |
| Janelle Gordon | Vice Operations | Profile | |
| Shafique MD | Interim Officer | Profile | |
| Lina Nilsson | Senior Platform | Profile |